Based on the standardised immunohistochemistry technique, the authors reported that HER2-low-positive tumour can be identified as a new subgroup of breast cancer with distinct biology and show differences in hormone receptor status, tumour proliferation, grading, and response to neoadjuvant therapy. Here, ERBB2 is linked to breast cancer.